BMY Bristol-Myers Squibb Company Common Stock
$67,40
Precio · Ago 25, 2026
Fundamentales a fecha de Jul 30, 2026
Rango 52S
$43–$69
95% of range
Calificación del Analista
HOLD
35 analysts
Precio Objetivo
$66
P/E (TTM)
15.6
ROE
40.5%
Margen de Beneficio Neto
14.6%
Acerca de Bristol-Myers Squibb Company Common Stock Descripción general de la empresa de Wikipedia
Bristol-Myers Squibb, a menudo conocido como BMS, es una compañía farmacéutica, con sede en la ciudad de Nueva York. La empresa se formó en 1989, tras la fusión de sus predecesores de Bristol-Myers y la Corporación de Squibb. Squibb fue fundado en 1858 por Edward Robinson Squibb en Brooklyn, Nueva York, mientras que Bristol-Myers fue fundada en 1887 por William McLaren Bristol y John Ripley Myers en Clinton, Condado de Oneida, Nueva York, (ambos eran graduados de Hamilton College. Bristol-Myers Squibb fabrica productos farmacéuticos de prescripción en varias áreas terapéuticas, incluyendo cáncer, VIH/SIDA, enfermedades cardiovasculares, diabetes, hepatitis, artritis reumatoide y trastornos psiquiátricos. Su misión es "descubrir, desarrollar y ofrecer medicamentos innovadores que ayudan a los pacientes a superar enfermedades graves". Sitios primarios de R & D 'BMS se encuentran en Princeton, New Jersey y Wallingford, Connecticut, con otros sitios en Hopewell y Nueva Brunswick, Nueva Jersey y en Braine-l ' Alleud, Bélgica, Tokio y Bangalore, India.
Leer más
Bristol-Myers Squibb, a menudo conocido como BMS, es una compañía farmacéutica, con sede en la ciudad de Nueva York. La empresa se formó en 1989, tras la fusión de sus predecesores de Bristol-Myers y la Corporación de Squibb. Squibb fue fundado en 1858 por Edward Robinson Squibb en Brooklyn, Nueva York, mientras que Bristol-Myers fue fundada en 1887 por William McLaren Bristol y John Ripley Myers en Clinton, Condado de Oneida, Nueva York, (ambos eran graduados de Hamilton College (Nueva York). Bristol-Myers Squibb fabrica productos farmacéuticos de prescripción en varias áreas terapéuticas, incluyendo cáncer, VIH/SIDA, enfermedades cardiovasculares, diabetes, hepatitis, artritis reumatoide y trastornos psiquiátricos. Su misión es "descubrir, desarrollar y ofrecer medicamentos innovadores que ayudan a los pacientes a superar enfermedades graves". Sitios primarios de R & D 'BMS se encuentran en Princeton, New Jersey (anteriormente Squibb) y Wallingford, Connecticut (anteriormente Bristol-Myers), con otros sitios en Hopewell y Nueva Brunswick, Nueva Jersey y en Braine-l ' Alleud, Bélgica, Tokio y Bangalore, India.
Historia
En 1999, el Presidente Bill Clinton otorgó a Bristol-Myers Squibb la Medalla Nacional de Tecnología, máximo reconocimiento de la nación para logros, muy bien tecnológicos "por extender y mejorar la vida humana a través de la investigación farmacéutica innovadora y el desarrollo y la redefinición de la ciencia del estudio clínico a través de ensayos clínicos innovadores y enormemente complejos que son modelos reconocidos en la industria." En 2005, BMS estaba entre las 53 entidades que contribuyeron el máximo de $250,000 a la investidura presidencial de Bush. En noviembre de 2009, Bristol-Myers Squibb anunció que era "partner" de Mead Johnson Nutrition, ofreciendo a los accionistas BMY la oportunidad de intercambiar sus acciones por las de Mead Johnson. Con el acuerdo con Bristol-Myers Squibb, se esperaba que este movimiento agudizase el enfoque de la compañía en productos biofarmacéuticos.
BMS es una compañía del Fortune 500 (#114 en la lista de 2010). 2009 Verde Ranking de Newsweek había reconocido a Bristol-Myers Squibb dentro del grupo de las 8 corporaciones más grandes de Estados Unidos. También, BMS fue incluida en el índice del Dow Jones Sustainability Norteamérica 2009 de compañías basadas en la sostenibilidad. En octubre de 2010, la compañía adquirió ZymoGenetics, asegurando la producción de medicamentos contra el cáncer, la hepatitis C y otras áreas terapéuticas.
En enero de 2019, la Justicia de EE.UU demandó al grupo farmacéutico Bristol-Myers Squibb, por participar en la década de 1940 en un experimento que afectó, con distintas enfermedades venéreas como sífilis y gonorrea, a miles de guatemaltecos.
Taxol
Al mismo tiempo, BMS celebró el contrato solitario para cosechar la corteza de árboles en peligro de extinción de Taxus brevifolia en territorio de Estados Unidos para la fabricación de medicinas de quimioterapia (Taxol). La producción actual proviene de fuentes renovables. BMS también celebró la licencia original de paclitaxel, pero ahora hay varios productores genéricos.
Fuente: Wikipedia, CC BY-SA 4.0 · Ver en Wikipedia ↗
BMY Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$67.40
Capitalización Bursátil
—
P/E (TTM)
15.6
BPA (TTM)
$3.46
Ingresos (TTM)
$48.19B
Rendimiento div.
—
ROE
40.5%
Deuda/Capital
2.5
Rango 52S
$43 – $69
BMY Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$48.19B
2019-12-31
→
2025-12-31
BPA
$3.46
2019-12-31
→
2025-12-31
Flujo de caja libre
$12.85B
2019-12-31
→
2025-12-31
Márgenes
14.6%
2019-12-31
→
2020-12-31
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
BMY
Mediana de Pares
P/E (TTM)
15.6
32.1
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
BMY
Mediana de Pares
Net Profit Margin (Margen de Beneficio Neto)
14.6%
13.0%
ROA
7.7%
6.4%
ROE
40.5%
15.1%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
BMY
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
2.5
—
Current Ratio (Ratio corriente)
1.3
1.6
Quick Ratio (Ratio Rápido)
0.8
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
BMY
Mediana de Pares
Revenue YoY (Ingresos interanuales)
-0.22%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
1.5%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
2.5%
—
EPS YoY (EPS interanual)
30.9%
—
Net Income YoY (Beneficio Neto interanual)
26.8%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
BMY
Mediana de Pares
Payout Ratio (Ratio de Pago)
71.5%
—
Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años
Rendimiento por Dividendo
—
Ratio de Pago
71.5%
CAGR de Dividendos a 5 años
—
| Fecha ex-dividendo | Monto |
|---|---|
| 2 de julio de 2026 | $0,6300 |
| 2 de abril de 2026 | $0,6300 |
| 2 de enero de 2026 | $0,6300 |
| 3 de octubre de 2025 | $0,6200 |
| 3 de julio de 2025 | $0,6200 |
| 4 de abril de 2025 | $0,6200 |
| 3 de enero de 2025 | $0,6200 |
| 4 de octubre de 2024 | $0,6000 |
| 5 de julio de 2024 | $0,6000 |
| 4 de abril de 2024 | $0,6000 |
| 4 de enero de 2024 | $0,6000 |
| 5 de octubre de 2023 | $0,5700 |
| 6 de julio de 2023 | $0,5700 |
| 6 de abril de 2023 | $0,5700 |
| 5 de enero de 2023 | $0,5700 |
| 6 de octubre de 2022 | $0,5400 |
| 30 de junio de 2022 | $0,5400 |
| 31 de marzo de 2022 | $0,5400 |
| 6 de enero de 2022 | $0,5400 |
| 30 de septiembre de 2021 | $0,4900 |
BMY Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
35 analistas
- Compra fuerte 6 17,1%
- Compra 8 22,9%
- Mantener 19 54,3%
- Venta 2 5,7%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
24 analistas · 2026-08-24
Mediana
$68.00
Ahora
$67.40
Mín
$40.00
Máx
$80.00
Objetivo mediano
$68.00
+0,9%
Objetivo medio
$66.21
-1,8%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.25%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $2.04 | $1.60 | 0.44% |
| 31 de marzo de 2026 | $1.58 | $1.43 | 0.15% |
| 31 de diciembre de 2025 | $1.26 | $1.13 | 0.13% |
| 30 de septiembre de 2025 | $1.63 | $1.52 | 0.11% |
| 30 de junio de 2025 | $1.46 | $1.08 | 0.38% |
| 31 de marzo de 2025 | $1.80 | $1.51 | 0.29% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
Balance general 31
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
Flujo de Efectivo 19
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
Rentabilidad 6
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
Tasas de Crecimiento 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 6
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
Balance general 29
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
Flujo de Efectivo 19
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
Valoración (TTM) 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Beneficio neto | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| EPS Diluido | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| Ratio corriente | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| Ratio Rápido | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 2 785 declarantes · $58.1B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 159 (-159 vs trimestre anterior) | 154 (+18 vs trimestre anterior) | 1 006 (-29 vs trimestre anterior) | 987 (+89 vs trimestre anterior) | +55.3M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7 682 927 263 | 133 337 856 | 13,22% | Acciones |
| STATE STREET CORP | $5 900 803 123 | 102 408 940 | 10,15% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3 894 809 793 | 67 594 755 | 6,70% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $2 858 273 235 | 49 750 183 | 4,92% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 700 823 125 | 46 873 015 | 4,65% | Acciones |
| NORGES BANK | $2 124 256 834 | 36 866 658 | 3,66% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $1 436 115 120 | 24 923 900 | 2,47% | Acciones |
| AMERIPRISE FINANCIAL INC | $1 308 030 705 | 22 705 049 | 2,25% | Acciones |
| Independent Franchise Partners LLP | $1 255 703 498 | 21 792 841 | 2,16% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $938 463 230 | 16 287 109 | 1,61% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $660 776 941 | 11 467 840 | 1,14% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $585 933 423 | 10 168 924 | 1,01% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $581 119 768 | 10 085 383 | 1,00% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494 716 447 | 8 585 846 | 0,85% | Acciones |
| BlackRock, Inc. | $492 399 085 | 8 545 628 | 0,85% | Acciones |
| FMR LLC | $451 250 223 | 7 831 486 | 0,78% | Acciones |
| TWO SIGMA ADVISERS, LP | $446 094 588 | 8 270 200 | 0,77% | Acciones |
| Robeco Institutional Asset Management B.V. | $417 435 581 | 7 244 630 | 0,72% | Acciones |
| GOLDMAN SACHS GROUP INC | $392 167 333 | 6 806 097 | 0,67% | Acciones |
| FIRST TRUST ADVISORS LP | $344 672 508 | 5 981 822 | 0,59% | Acciones |
| Capital International Investors | $340 767 005 | 5 913 752 | 0,59% | Acciones |
| Swiss National Bank | $331 822 056 | 5 758 800 | 0,57% | Acciones |
| VAN ECK ASSOCIATES CORP | $325 076 944 | 5 641 738 | 0,56% | Acciones |
| National Pension Service | $321 412 139 | 5 578 135 | 0,55% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319 229 612 | 5 540 268 | 0,55% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $316 480 270 | 5 492 542 | 0,54% | Acciones |
| Legal & General Group Plc | $315 258 552 | 5 471 339 | 0,54% | Acciones |
| M&G PLC | $306 949 282 | 5 292 229 | 0,53% | Acciones |
| NORDEA INVESTMENT MANAGEMENT AB | $300 773 017 | 5 232 200 | 0,52% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $293 408 012 | 5 092 121 | 0,50% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $288 555 718 | 4 757 720 | 0,50% | Acciones |
| Vanguard Global Advisers, LLC | $270 856 466 | 4 700 737 | 0,47% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $266 201 519 | 4 619 950 | 0,46% | Acciones |
| California Public Employees Retirement System | $263 375 546 | 4 570 905 | 0,45% | Acciones |
| BANK OF AMERICA CORP /DE/ | $263 115 723 | 4 566 396 | 0,45% | Acciones |
| VANGUARD GROUP INC | $247 970 649 | 4 597 157 | 0,43% | Acciones |
| Caisse de depot et placement du Quebec | $243 646 343 | 4 228 503 | 0,42% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $241 222 903 | 4 186 444 | 0,42% | Acciones |
| JANE STREET GROUP, LLC | $224 896 622 | 3 903 100 | 0,39% | Opción de compra |
| WELLINGTON MANAGEMENT GROUP LLP | $214 546 630 | 3 723 475 | 0,37% | Acciones |
| Employees Provident Fund Board | $209 755 987 | 3 640 333 | 0,36% | Acciones |
| CITADEL ADVISORS LLC | $194 502 072 | 3 375 600 | 0,33% | Opción de venta |
| RHUMBLINE ADVISERS | $192 874 042 | 3 347 347 | 0,33% | Acciones |
| LPL Financial LLC | $188 151 217 | 3 265 381 | 0,32% | Acciones |
| BARCLAYS PLC | $186 163 076 | 3 230 876 | 0,32% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185 255 963 | 3 215 133 | 0,32% | Acciones |
| UBS Group AG | $180 243 196 | 3 128 136 | 0,31% | Acciones |
| Qube Research & Technologies Ltd | $178 273 860 | 3 093 958 | 0,31% | Acciones |
| Artemis Investment Management LLP | $175 941 518 | 3 053 480 | 0,30% | Acciones |
| SEB Asset Management AB | $165 520 833 | 2 872 632 | 0,28% | Acciones |
| Ensign Peak Advisors, Inc | $165 119 502 | 2 865 663 | 0,28% | Acciones |
| CITADEL ADVISORS LLC | $157 769 322 | 2 738 100 | 0,27% | Opción de compra |
| JANE STREET GROUP, LLC | $152 525 902 | 2 647 100 | 0,26% | Opción de venta |
| NATIXIS | $145 152 674 | 2 519 137 | 0,25% | Acciones |
| AustralianSuper Pty Ltd | $140 209 857 | 2 433 354 | 0,24% | Acciones |
| Mirae Asset Global Investments Co., Ltd. | $138 044 440 | 2 395 773 | 0,24% | Acciones |
| Bank of New York Mellon Corp | $136 334 163 | 2 366 091 | 0,23% | Acciones |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132 803 901 | 2 304 823 | 0,23% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $132 622 456 | 2 301 674 | 0,23% | Acciones |
| Capital World Investors | $129 313 224 | 2 244 242 | 0,22% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $129 300 432 | 2 244 020 | 0,22% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125 419 207 | 2 176 661 | 0,22% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $123 353 032 | 2 140 802 | 0,21% | Acciones |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122 879 893 | 2 132 591 | 0,21% | Acciones |
| PFA Pension, Forsikringsaktieselskab | $121 829 832 | 2 114 367 | 0,21% | Acciones |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120 528 714 | 2 234 496 | 0,21% | Acciones |
| MACKENZIE FINANCIAL CORP | $118 944 044 | 2 064 284 | 0,20% | Acciones |
| Pictet Asset Management Holding SA | $116 783 155 | 2 026 687 | 0,20% | Acciones |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116 161 574 | 2 015 994 | 0,20% | Acciones |
| TD Asset Management Inc | $115 669 154 | 2 007 448 | 0,20% | Acciones |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115 240 000 | 2 000 000 | 0,20% | Opción de compra |
| MACQUARIE GROUP LTD | $111 978 478 | 1 943 396 | 0,19% | Acciones |
| Vinva Investment Management Ltd | $109 557 913 | 1 870 866 | 0,19% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $108 509 833 | 1 883 218 | 0,19% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106 751 521 | 1 760 124 | 0,18% | Acciones |
| LMR Partners LLP | $106 066 896 | 1 840 800 | 0,18% | Opción de venta |
| AVIVA PLC | $103 620 639 | 1 798 345 | 0,18% | Acciones |
| PRUDENTIAL FINANCIAL INC | $103 202 606 | 1 791 090 | 0,18% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102 378 000 | 1 776 782 | 0,18% | Acciones |
| STOREBRAND ASSET MANAGEMENT AS | $101 037 131 | 1 753 508 | 0,17% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100 790 172 | 1 749 222 | 0,17% | Acciones |
| BANK OF NOVA SCOTIA | $99 453 647 | 1 726 026 | 0,17% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98 875 920 | 1 716 000 | 0,17% | Acciones |
| KLP KAPITALFORVALTNING AS | $94 673 002 | 1 643 058 | 0,16% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90 576 678 | 1 567 009 | 0,16% | Acciones |
| BANK OF MONTREAL /CAN/ | $89 684 378 | 1 556 480 | 0,15% | Acciones |
| Douglas Lane & Associates, LLC | $89 667 305 | 1 556 184 | 0,15% | Acciones |
| PNC Financial Services Group, Inc. | $89 112 096 | 1 546 548 | 0,15% | Acciones |
| Walleye Trading LLC | $88 014 550 | 1 527 500 | 0,15% | Opción de compra |
| Korea Investment CORP | $86 518 389 | 1 501 534 | 0,15% | Acciones |
| APG Asset Management N.V. | $85 242 422 | 1 691 386 | 0,15% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85 175 958 | 1 478 236 | 0,15% | Acciones |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84 205 059 | 1 764 695 | 0,14% | Acciones |
| Mariner, LLC | $83 309 670 | 1 445 809 | 0,14% | Acciones |
| Retirement Systems of Alabama | $80 928 212 | 1 404 516 | 0,14% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $80 695 542 | 1 400 478 | 0,14% | Acciones |
| Nuveen Asset Management, LLC | $76 733 142 | 1 356 668 | 0,13% | Acciones |
| CWM, LLC | $76 220 909 | 1 256 734 | 0,13% | Acciones |
| Eurizon Capital SGR S.p.A. | $70 986 984 | 1 230 296 | 0,12% | Acciones |
| Aberdeen Group plc | $70 798 674 | 1 228 717 | 0,12% | Acciones |
Informantes de la empresa 102 insiders · 65 directivos · 37 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13 de junio de 2025 G | 125 439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 8 de septiembre de 2006 F | 571 673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 1 de abril de 2026 S | 159 248 | 0 | 3 | $-4 500 496 |
| Jean-Marc Huet | EVP & CFO | 30 de abril de 2009 P | 25 000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 9 de mayo de 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10 de marzo de 2025 A | 4 711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2 de marzo de 2004 A | 178 889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10 de septiembre de 2003 A | 60 000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 1 de agosto de 2026 M | 24 997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 1 de agosto de 2026 M | 13 649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 3 de junio de 2026 F | 12 081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 1 de julio de 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 1 de mayo de 2025 J | 12 439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25 de abril de 2025 P | 83 513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1 de abril de 2025 M | 13 797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10 de marzo de 2025 A | 14 967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10 de marzo de 2025 A | 5 196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10 de marzo de 2025 A | 16 102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10 de marzo de 2025 A | 15 839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10 de marzo de 2025 A | 364 296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10 de marzo de 2024 M | 432 266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24 de agosto de 2023 S | 27 868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 1 de julio de 2023 M | 3 453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 3 de mayo de 2023 S | 47 751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2 de mayo de 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 1 de abril de 2023 M | 34 734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14 de marzo de 2022 S | 16 704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24 de noviembre de 2021 S | 63 536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30 de julio de 2021 S | 13 777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 3 de junio de 2021 M | 9 485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10 de mayo de 2021 S | 31 956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10 de marzo de 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10 de marzo de 2020 M | 70 946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10 de marzo de 2020 M | 137 534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2 de octubre de 2019 M | 6 214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 3 de abril de 2019 M | 22 223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 1 de agosto de 2018 M | 49 424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 6 de septiembre de 2017 S | 46 297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 3 de septiembre de 2017 M | 37 974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10 de marzo de 2017 A | 20 138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10 de marzo de 2017 M | 321 906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13 de marzo de 2015 S | 31 015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 1 de julio de 2014 M | 94 374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10 de marzo de 2014 A | 4 174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 3 de junio de 2013 M | 148 221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31 de mayo de 2013 S | 173 375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 6 de marzo de 2012 M | 142 142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 1 de octubre de 2011 M | 43 689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14 de junio de 2011 M | 7 578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13 de mayo de 2011 M | 203 170 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 11 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 presentaciones | 16 de julio de 2020 | — | Presentación inicial | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27 de febrero de 2019 | — | Presentación inicial | Inversión pasiva | SEC |
| S.S. OR ×3 presentaciones | 23 de diciembre de 2009 | — | Presentación inicial | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25 de noviembre de 2009 | — | Presentación inicial | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 presentaciones | 27 de febrero de 2009 | — | Presentación inicial | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 presentaciones | 8 de octubre de 2008 | — | Presentación inicial | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 presentaciones | 6 de junio de 2003 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 16 de abril de 2003 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 3 de febrero de 2003 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 6 de marzo de 2002 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 6 de febrero de 2002 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 296 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6,29% | 39 590 NS | 30 de junio de 2026 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1 134 150 SH | 21 de agosto de 2026 | Diario |
| ROPE · EA Series Trust | 4,97% | 7 379 NS | 29 de mayo de 2026 | N-PORT |
| IHE · iShares Trust | 4,65% | 1 223 984 SH | 21 de agosto de 2026 | Diario |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44 768 NS | 30 de abril de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6 427 NS | 30 de abril de 2026 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3,43% | 4 337 329 NS | 30 de junio de 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101 680 NS | 31 de mayo de 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2 332 NS | 30 de abril de 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42 594 NS | 31 de mayo de 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48 641 121 NS | 31 de mayo de 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,78% | 224 546 SH | 21 de agosto de 2026 | Diario |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226 688 NS | 30 de abril de 2026 | N-PORT |
| HDV · iShares Trust | 2,62% | 6 134 190 SH | 21 de agosto de 2026 | Diario |
| ACEP · EA Series Trust | 2,52% | 44 211 NS | 29 de mayo de 2026 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234 394 NS | 31 de mayo de 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210 030 NS | 31 de mayo de 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148 728 NS | 31 de mayo de 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1 612 NS | 30 de abril de 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,10% | 38 747 SH | 21 de agosto de 2026 | Diario |
| HRTS · Tema ETF Trust | 2,09% | 18 939 NS | 31 de mayo de 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24 896 NS | 30 de abril de 2026 | N-PORT |
| IYH · iShares Trust | 2,06% | 1 218 183 SH | 21 de agosto de 2026 | Diario |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1 086 835 SH | 21 de agosto de 2026 | Diario |
| GCOW · Pacer Funds Trust | 2,03% | 1 123 894 NS | 30 de abril de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6 082 360 NS | 30 de abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15 628 NS | 30 de abril de 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30 055 NS | 30 de abril de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938 456 NS | 30 de abril de 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1 422 NS | 30 de abril de 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,93% | 31 120 SH | 21 de agosto de 2026 | Diario |
| PEY · Invesco Exchange-Traded Fund Trust | 1,83% | 327 924 SH | 21 de agosto de 2026 | Diario |
| SDOG · ALPS ETF Trust | 1,83% | 441 820 NS | 31 de mayo de 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27 812 NS | 31 de mayo de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,78% | 40 606 NS | 30 de abril de 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8 912 NS | 31 de mayo de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,73% | 6 137 665 SH | 19 de agosto de 2026 | Diario |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 213 437 SH | 21 de agosto de 2026 | Diario |
| RXL · ProShares Trust | 1,68% | 21 228 NS | 31 de mayo de 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26 358 NS | 31 de mayo de 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 1,65% | 12 671 NS | 30 de abril de 2026 | N-PORT |
| IXJ · iShares Trust | 1,61% | 1 073 117 SH | 21 de agosto de 2026 | Diario |
| NULV · Nushares ETF Trust | 1,57% | 539 514 NS | 30 de abril de 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13 556 NS | 30 de abril de 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11 473 NS | 30 de abril de 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 415 736 SH | 21 de agosto de 2026 | Diario |
| COWG · Pacer Funds Trust | 1,47% | 526 151 NS | 30 de abril de 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68 134 NS | 30 de abril de 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21 473 NS | 31 de mayo de 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64 178 NS | 30 de abril de 2026 | N-PORT |